CytomX Therapeutics (NasdaqGS:CTMX) FY Conference Transcript

Summary of CytomX Therapeutics FY Conference Call Company Overview - Company: CytomX Therapeutics (NasdaqGS:CTMX) - Location: South San Francisco, California - Focus: Development of Probody therapeutic pipeline for oncology addressing unmet needs [1][2] Core Technology and Partnerships - Technology: Probody therapeutic platform utilizing antibody masking to enhance therapeutic window for oncology products [1][2] - Partnerships: Collaborations with Bristol Myers Squibb and Moderna, primarily in T-cell engager space [2] Financial Position - Cash Position: Raised $100 million in Q2 2025, providing cash runway into Q2 2027, excluding milestones or new business development [2] Clinical Programs CX2051 (EpCAM Targeting Probody Topoisomerase 1 ADC) - Clinical Focus: Targeting colorectal cancer (CRC), a major unmet need in oncology [5][6] - Phase One Data: - 28% confirmed overall response rate in metastatic CRC - 94% disease control rate - Preliminary progression-free survival (PFS) of 5.8 months [8][16] - Safety Profile: Favorable safety with no dose-limiting toxicities observed; manageable adverse events [16][17] - Next Steps: - Expansion of clinical study cohorts to 20 patients per cohort - Potential registrational study initiation in late line therapy in 2026 [17][18] - Exploration of earlier treatment lines and combination studies [18][20] CX801 (Probody Interferon Alpha 2B) - Clinical Focus: Cancer immunotherapy, particularly in late-stage melanoma [21][24] - Mechanism: Engineered as a dually masked Interferon to activate immune response locally in the tumor microenvironment [23] - Combination Study: Initiated combination study with Keytruda, with initial biomarker data expected later this year and clinical results in 2026 [24][25] Market Potential - CX2051: Potentially first-in-class ADC with multi-billion dollar annual sales potential, particularly in late line metastatic CRC [20] - Broader Applications: EpCAM target may have potential across multiple solid tumors, indicating significant market opportunities beyond CRC [19][20] Conclusion - CytomX Therapeutics is positioned to advance its innovative Probody therapeutic pipeline with promising early clinical data, strong financial backing, and strategic partnerships, aiming to address significant unmet needs in oncology and potentially transform treatment paradigms in colorectal cancer and melanoma [25]